University of Glasgow

Equine Virology Research Foundation

Akzo Nobel N.v.

Lesley Nicolson

David Edward Onions

Paulus Jacobus Sondermeijer

Martha Jacoba Willemse

The present invention involves isolated equine herpesvirus-4 (EHV-4) or gH or gC polypeptides and antigenic fragments. Methods of using the polypeptides and the fragments thereof are also presented.

EHV-4 gH or gC glycoprotein polypeptides and methods of use

An Equine herpesvirus-4 (EHV-4) mutant which does not produce a functional thymidine kinase due to a deletion and/or insertion in the gene encoding thymidine kinase, the deletion and/or insertion made at a position within the thymidine kinase gene such as to not substantially alter expression of the UL24 gene. Recombinant DNA comprising DNA of the EHV-4 mutant, host cells containing the recombinant DNA, and a process for the preparation of the EHV-4 mutant.

Equine herpesvirus-4TK mutant

The present invention involves isolated nucleic acid molecules encoding the equine herpesvirus-4 (EHV-4) gH or gC polypeptide, the polypeptides so encoded, and antigenic fragments thereof. Vectors and host cells containing these nucleic acid sequences, and uses thereof, are presented.

DNA encoding the EHV-4 gH or gC glycoprotein

The present invention relates to an Equine herpesvirus (EHV) vaccine comprising an EHV having an insertion or deletion in the gene 15 of the EHV genome.

Growing community of inventors

Glasgow, United Kingdom

Lesley Nicolson